Back to top

Roth starts Castle Biosciences at Buy, notes quality revenue growth outlook

Roth Capital initiated coverage of Castle Biosciences (CSTL) with a Buy rating and $40 price target The firm believes Castle should be owned for it...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Castle Biosciences, Inc. (CSTL)